HDAC9 and leukemia: The Acute Leukemia French Association Group trial (ALFA-9802) (7) compared HDAC (3 g/m2) consolidation regimen with a timed-sequential consolidation regimen consisting of etoposide, mitoxantrone, and cytarabine (500 mg/m2, d1-d5) and showed the HDAC regimen was more beneficial for patient survival.